Phase 3 N=122 Japan Long-term Safety for Tiotropium Plus Olodaterol
Pulmonary Disease, Chronic Obstructive
Primary: Number (%) of Patients With Drug-related AEs — 4.9; 5.0; 7.3 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=339 Effect of Triptorelin (Decapeptyl®) 22.5 mg on Two Biomarkers in Patients With Advanced Prostate Cancer
Prostate Cancer
Primary: PCA3 Score Expressed as a Ratio of PCA3 mRNA (Messenger Ribonucleic Acid) Over PSA (Prostate Specific Antigen) mRNA — 232; 27; 10; 24 participants
Phase 3 N=202 Synchronized Transcranial Magnetic Stimulation (sTMS) in Major Depressive Disorder
Major Depressive Disorder
Primary: Mean HAM-D17 Total Score Change (Intent to Treat - All) — -7.49; -6.97 units on a scale
Phase 3 N=34 Duragen Versus Duraguard in Chiari Surgery
Chiari Malformation
Primary: Physical Health Quality of Life — 31.4; 35.61 units on a scale
Phase 3 N=31 Omega-3 Fatty Acids and Insulin Sensitivity
Insulin Resistance
Primary: Insulin Sensitivity by Hyperinsulinemic-euglycemic Clamp at Baseline and 6 Month Follow up — 10.92; 10.39; 10.16; 10.80 mg/kg FFM/min
Phase 3 N=88 A Study Evaluating IL28B Polymorphism in Patients With HBeAg-Negative Chronic Hepatitis B Treated With Pegasys (Peginterferon Alfa-2a) in Study ML18253
Hepatitis B, Chronic
Primary: Percentage of Participants With Sustained Viral Response (SVR) Defined as HBV DNA ≤ 2000 IU/ml at IL28B Genotype rs12979860 at End of Follow-up (EoF) — 20.0; 17.1; 20.0…
Phase 3 N=559 A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
Pulmonary Disease, Chronic Obstructive
Primary: Mean Change From Baseline (BL) in Aortic Pulse Wave Velocity (aPWV) at the End of the 24-week Treatment Period (Day 168) — -1.97; -1.95; -1.75 meters per second (m/sec)…
Phase 3 N=2,583 Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
Irritable Bowel Syndrome With Diarrhea
Primary: Repeat Treatment Responders — 32.6; 25.0 percentage of patients — p=0.0232
Phase 3 N=792 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma
Relapsed Multiple Myeloma
Primary: Progression-free Survival (PFS) — 17.6; 26.3 months — p=< 0.0001
Phase 3 N=150 Efficacy of Oral Famciclovir 125mg Comparing to Aciclovir 200 mg Treatment in Patients With Active Recurrent Genital Herpes
GENITAL HERPES
Primary: Efficacy Will be Evaluated by the Proportion of Subjects With Non Herpes Manifestation — 73; 52 subjects
Phase 3 N=152 Preoperative Single-dose Steroid Application for the Treatment of Nausea and Vomiting After Thyroid Surgery
Thyroidectomy · Thyroid Diseases
Primary: Incidence of Postoperative Nausea and Vomiting — 29; 57 percentage of participants — p=0.001
Phase 3 N=192 Rollover Study of VX-770 in Cystic Fibrosis Subjects
Cystic Fibrosis
Primary: Number of Participants With Non-Serious Adverse Events (AEs) and Serious Adverse Events (SAEs) — 190; 70 participants
Phase 3 N=480 Brief Strategic Family Therapy for Adolescent Drug Abusers
Substance Abuse
Primary: Main Study, Adolescent Drug Use — 3; 3 days of drug use 28 days prior baseline — p=.27
Phase 3 N=84 Patient Experience Study of Deoxycholic Acid Injection
Moderate or Severe Submental Fullness
Primary: Change From Baseline in Pain Visual Analog Scale Scores — 0.0; 0.0; 0.0; 0.0 units on a scale — p=0.6803
Phase 3 N=799 Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer
Estrogen Receptor Negative · Estrogen Receptor Positive · HER2/Neu Negative
Primary: Progression Free Survival — 10.97; 9.3; 7.36 months — p=0.054